The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: Elevated levels of amyloid deposition as well as white matter damage are thought to be risk factors for Alzheimer Disease (AD). Here we examined whether qualitative ratings of white matter damage predicted cognitive impairment beyond measures of amyloid. MATERIALS AND METHODS: The study examined 397 cognitively normal, 51 very mildly demented, and 11 mildly demented individuals aged 42-90 (mean 68.5). Participants obtained a T2-weighted scan as well as a positron emission tomography scan using (11)[C] Pittsburgh Compound B. Periventricular white matter hyperintensities (PVWMHs) and deep white matter hyperintensities (DWMHs) were measured on each T2 scan using the Fazekas rating scale. The effects of amyloid deposition and white matter damage were assessed using logistic regressions. RESULTS: Levels of amyloid deposition (ps < 0.01), as well as ratings of PVWMH (p < 0.01) and DWMH (p < 0.05) discriminated between cognitively normal and demented individuals. CONCLUSIONS: The amount of amyloid deposition and white matter damage independently predicts cognitive impairment. This suggests a diagnostic utility of qualitative white matter scales in addition to measuring amyloid levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 2×
“Research examining AD biomarkers suggests a rise in underlying pathology a decade or more before the onset of dementia, and continuing throughout the early stages of the disease (Bateman et al., 2012; Benzinger et al., 2013; Jack et al., 2010).”
Self-citationForecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Debette, S., & Markus, H. S. (2010) · BMJ · doi:10.1136/bmj.c3666 · Cited by 2,328 · cited 2×
“In general there is a rising interest on the clinical importance of WMH across diseases (Debette and Markus, 2010).”
Longstreth, W. T., Manolio, T. A., Arnold, A., Burke, G. L., Bryan, N., Jungreis, C. A., Enright, P. L., O'Leary, D., & Fried, L. (1996) · Stroke · doi:10.1161/01.str.27.8.1274 · Cited by 1,464 · cited 1×
“Usingsemi-quantitativescales,whitematter lesionshaveoftenbeen seen in individuals with compromised cardiovascular systems (Breteler et al., 1994; Longstreth et al., 1996).”
Hensley, K., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., & Butterfield, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3270 · Cited by 1,086 · cited 1×
“A β leads to oxidative damage and the formation of free radicals (Hensley et al., 1994; Park et al., 2004; Thomas et al., 1996), and the administration of A β damages oligodendrocytes in vitro (Roth et al., 2005) and in vivo (Jantaratnotai et al., 2003).”
β-Amyloid-mediated vasoactivity and vascular endothelial damage
Thomas, T., Thomas, G., McLendon, C., Sutton, T., & Mullan, M. (1996) · Nature · doi:10.1038/380168a0 · Cited by 703 · cited 1×
“A β leads to oxidative damage and the formation of free radicals (Hensley et al., 1994; Park et al., 2004; Thomas et al., 1996), and the administration of A β damages oligodendrocytes in vitro (Roth et al., 2005) and in vivo (Jantaratnotai et al., 2003).”
Head, D. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh003 · Cited by 645
Mayeux, R., Ottman, R., Maestre, G., Ngai, C., Tang, M.-X., Ginsberg, H., Chun, M., Tycko, B., & Shelanski, M. (1995) · Neurology · doi:10.1212/wnl.45.3.555 · Cited by 590
Bozzali, M. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.742 · Cited by 568
Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546 · cited 2×
“Consistent with these results, there has been a suggestion that AD may have a larger vascular component than often recognized (Bartzokis, 2011; de la Torre, 2010; Launer, 2002).”
Debette, S., Beiser, A., DeCarli, C., Au, R., Himali, J. J., Kelly-Hayes, M., Romero, J. R., Kase, C. S., Wolf, P. A., & Seshadri, S. (2010) · Stroke · doi:10.1161/strokeaha.109.570044 · Cited by 508 · cited 2×
“In general there is a rising interest on the clinical importance of WMH across diseases (Debette and Markus, 2010).”
Schmidt, R., Ropele, S., Enzinger, C., Petrovic, K., Smith, S., Schmidt, H., Matthews, P. M., & Fazekas, F. (2005) · Annals of Neurology · doi:10.1002/ana.20630 · Cited by 408
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317918110 · Cited by 391
Self-citationHistopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging
Scheltens, P., Barkhof, F., Leys, D., Wolters, E. C., Ravid, R., & Kamphorst, W. (1995) · Neurology · doi:10.1212/wnl.45.5.883 · Cited by 344 · cited 4×
“In this initial work the most common way to characterize white matter damage was to use semi-quantitative scales (Fazekas et al., 1987; Kapeller et al., 2003; Scheltens et al., 1995) to grade the severity of white matter hyperintensities (WMHs) on T 2 -weighted or fl uid-attenuated inversion recovery (FLAIR) scans.”
InfluentialPlasma β-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy
Gurol, M. E., Irizarry, M. C., Smith, E. E., Raju, S., Diaz-Arrastia, R., Bottiglieri, T., Rosand, J., Growdon, J. H., & Greenberg, S. M. (2006) · Neurology · doi:10.1212/01.wnl.0000191403.95453.6a · Cited by 339 · cited 1×
“Such results can been seen in the literature as circulating levels of A β are associated with WMH (Gurol et al., 2006), and baseline levels of white matter lesions predict an accelerated accumulation of amyloid over time (Grimmer et al., 2012).”
Head injury as a risk factor for Alzheimer's disease
Mortimer, J. A., French, L. R., Hutton, J. T., & Schuman, L. M. (1985) · Neurology · doi:10.1212/wnl.35.2.264 · Cited by 309
Provenzano, F. A., Muraskin, J., Tosto, G., Narkhede, A., Wasserman, B. T., Griffith, E. Y., Guzman, V. A., Meier, I. B., Zimmerman, M. E., Brickman, A. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1321 · Cited by 192
Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging
Rezek, D. L., Morris, J. C., Fulling, K. H., & Gado, M. H. (1987) · Neurology · doi:10.1212/wnl.37.8.1365 · Cited by 173 · cited 1×
“Early work with computed tomography (CT) images noted increased incidence of white matter leukoaraiosis in individuals with AD (Blennow et al., 1991; Rezek et al., 1987).”
Self-citation
Cited by
Gordon, B. A., Friedrichsen, K., Brier, M., Blazey, T., Su, Y., Christensen, J., Aldea, P., McConathy, J., Holtzman, D. M., Cairns, N. J., et al. (2016) · Brain · doi:10.1093/brain/aww139 · Cited by 184
Self-citationLongitudinal brain imaging in preclinical Alzheimer disease: impact of APOE ε4 genotype
Mishra, S., Blazey, T. M., Holtzman, D. M., Cruchaga, C., Su, Y., Morris, J. C., Benzinger, T. L. S., & Gordon, B. A. (2018) · Brain · doi:10.1093/brain/awy103 · Cited by 151
Self-citationWhite matter hyperintensities across the adult lifespan: Relation to age, Aβ load, and cognition
Garnier-Crussard, A., Bougacha, S., Wirth, M., André, C., Delarue, M., Landeau, B., Mézenge, F., Kuhn, E., Gonneaud, J., Chocat, A., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00669-4 · Cited by 130
Myelin changes at the early stage of 5XFAD mice
Gu, L., Wu, D., Tang, X., Qi, X., Li, X., Bai, F., Chen, X., Ren, Q., & Zhang, Z. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.12.013 · Cited by 87
Luo, J., Ma, Y., Agboola, F. J., Grant, E., Morris, J. C., McDade, E., Fagan, A. M., Benzinger, T. L. S., Hassenstab, J., Bateman, R. J., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207378 · Cited by 35
Self-citation
Metadata
- Authors
- Gordon, B. A., Najmi, S., Hsu, P., Roe, C. M., Morris, J. C., & Benzinger, T. L. S.
- Venue
- NeuroImage: Clinical
- Publisher
- Elsevier BV
- Published
- 2015
- Volume
- 8
- Pages
- 246-252
- ISSN
- 2213-1582 (ISSN-L)
- OpenAlex
- W2042009004
- Cited by
- 56
- References
- 19
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.